Xeris Pharmaceuticals (XERS)
(Delayed Data from NSDQ)
$1.90 USD
+0.01 (0.53%)
Updated May 14, 2024 04:00 PM ET
After-Market: $1.89 -0.01 (-0.53%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.90 USD
+0.01 (0.53%)
Updated May 14, 2024 04:00 PM ET
After-Market: $1.89 -0.01 (-0.53%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth F Momentum C VGM
Zacks News
Will Xeris Biopharma (XERS) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Xeris Biopharma (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xeris Pharmaceuticals (XERS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Xeris Pharmaceuticals (XERS) delivered earnings and revenue surprises of -32.26% and -11.16%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Xeris Pharmaceuticals (XERS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Xeris Pharmaceuticals (XERS) stock based on the movements in the options market lately.
Xeris Pharmaceuticals (XERS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xeris Pharmaceuticals (XERS) delivered earnings and revenue surprises of 3.23% and 6.42%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Xeris Pharmaceuticals (XERS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Xeris Pharmaceuticals (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xeris Pharmaceuticals (XERS) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Xeris Pharmaceuticals (XERS) delivered earnings and revenue surprises of -5.13% and -22.83%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Xeris Pharmaceuticals (XERS) is Overbought: Is A Drop Coming?
by Zacks Equity Research
Xeris Pharmaceuticals (XERS) has moved higher as of late, but there could definitely be trouble on the horizon for this company
Do Options Traders Know Something About Xeris Pharmaceuticals (XERS) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Xeris Pharmaceuticals (XERS) stock based on the movements in the options market lately.
Xeris Pharmaceuticals (XERS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xeris Pharmaceuticals (XERS) delivered earnings and revenue surprises of 35.19% and 111.33%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Pacira's (PCRX) Q3 Earnings Top Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Pacira's (PCRX) both bottom and the top line surpass estimates in Q3. Exparel sales rise year over year.
Xeris Pharmaceuticals (XERS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Xeris Pharmaceuticals (XERS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in Xeris Pharmaceuticals (XERS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Xeris Pharmaceuticals (XERS) stock based on the movements in the options market lately.
Xeris Pharmaceuticals (XERS) Looks Good: Stock Adds 5.1% in Session
by Zacks Equity Research
Xeris Pharmaceuticals (XERS) saw a big move last session, as its shares more than 5% on the day, amid huge volumes.
Xeris Pharmaceuticals, Inc. (XERS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Xeris Pharmaceuticals, Inc. (XERS) delivered earnings and revenue surprises of 11.27% and -11.18%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Xeris Pharmaceuticals, Inc. (XERS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Xeris Pharmaceuticals, Inc. (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xeris Pharmaceuticals (XERS) in Focus: Stock Moves 6.8% Higher
by Zacks Equity Research
Xeris Pharmaceuticals (XERS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Company News for May 26, 2020
by Zacks Equity Research
Companies In The News Are: TTWO, XERS, SPLK, NAVB
Xeris Pharmaceuticals Inc (XERS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Xeris Pharmaceuticals Inc (XERS) delivered earnings and revenue surprises of 3.26% and -7.91%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Xeris' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Xeris Pharmaceuticals.
Eiger Completes NDA Submission of Progeria Drug Lonafarnib
by Zacks Equity Research
Eiger (EIGR) completes rolling submission of the NDA seeking approval for lonafarnib as a treatment for progeria and progeroid laminopathies, ultra-rare diseases causing accelerated aging in children.
Xeris Pharmaceuticals, Inc. (XERS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xeris Pharmaceuticals, Inc. (XERS) delivered earnings and revenue surprises of 0.81% and 144.30%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Xeris Pharmaceuticals, Inc. (XERS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Xeris Pharmaceuticals, Inc. (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xeris Pharmaceuticals, Inc. (XERS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xeris Pharmaceuticals, Inc. (XERS) delivered earnings and revenue surprises of 3.17% and 61.50%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Xeris Pharmaceuticals, Inc. (XERS) Q3 Earnings Expected to Decline
by Zacks Equity Research
Xeris Pharmaceuticals, Inc. (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xeris Pharmaceuticals, Inc. (XERS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xeris Pharmaceuticals, Inc. (XERS) delivered earnings and revenue surprises of -31.96% and 57.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?